Teva Announces Virtual 2020 Annual Meeting of Shareholders
2020年5月26日 - 9:00PM
ビジネスワイヤ(英語)
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA)
(“Teva”), announced today that, in the interest of the health and
safety of its shareholders, directors, officers and employees in
light of the current COVID-19 pandemic, the format of its 2020
Annual Meeting of Shareholders has been changed to a virtual
meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June
9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as
previously announced.
Shareholders will not be able to physically attend the 2020
Annual Meeting.
To participate in the virtual 2020 Annual Meeting, holders of
Teva’s American Depositary Shares (“ADSs”) and ordinary shares
should visit www.meetingcenter.io/218625112 and, when prompted,
enter their control number (see below). The meeting password is
TEVA2020.
Holders of ADSs
Holders of ADSs as of the close of business on April 30, 2020
(the “Record Date”) will be able to participate in the virtual 2020
Annual Meeting and ask questions through the online meeting
platform.
Record holders of ADSs should enter the 15-digit control number
on the proxy card or Notice of Internet Availability of Proxy
Materials previously received.
Beneficial holders of ADSs that are registered in the name of a
broker, bank or other agent must register in advance to participate
in the virtual 2020 Annual Meeting and ask questions through the
online meeting platform. To register, beneficial holders of ADSs
must submit proof of ownership reflecting the number of ADSs
beneficially owned as of the Record Date, along with their name and
email address, to Computershare at legalproxy@computershare.com.
Requests for registration must be labeled as "TEVA MEETING REQUEST"
and must be received no later than Friday, June 5, 2020 at 9:30
a.m., New York time. Beneficial holders of ADSs will then receive a
confirmation of registration with a 15-digit control number by
email from Computershare.
Holders of Teva’s ADSs may not vote through the online meeting
platform. To vote, holders of ADSs should follow the instructions
set forth in Teva’s Proxy Statement filed with the Securities and
Exchange Commission on April 22, 2020.
Holders of Ordinary Shares
Holders of Teva’s ordinary shares as of the Record Date will be
able to participate in the virtual 2020 Annual Meeting, vote their
shares and ask questions through the online meeting platform. If a
holder of Teva’s ordinary shares would like to appoint another
person to act as his/her authorized proxy, such proxy must be
submitted along with an email address to Teva at
TevaAGM2020@tevapharm.com, must be labeled as “TEVA MEETING
REQUEST” and must be received no later than June 5, 2020 at 4:30
p.m., Israel time.
Record holders of ordinary shares must enter a control number to
access the online meeting platform. The control number will consist
of the holder’s Israeli identification number or Israeli company
registration number as it appears in Teva’s share register.
Holders of ordinary shares registered pursuant to Section 177(1)
of the Israeli Companies Law, 5759-1999 whose shares are held
through a nominee company (“Non-Registered Holders”) must register
in advance to participate in the virtual 2020 Annual Meeting, vote
their shares and ask questions through the online meeting platform.
To register, Non-Registered Holders must submit proof of ownership
(including Israeli identification number or company registration
number) reflecting the number of ordinary shares beneficially owned
as of the Record Date, along with their name and email address, to
Teva at TevaAGM2020@tevapharm.com. Requests for registration must
be labeled as “TEVA MEETING REQUEST” and must be received no later
than June 5, 2020 at 4:30 p.m., Israel time. Such Non-Registered
Holders will then be able to use their Israeli identification
number or company registration number as it appears on the proof of
ownership provided to Teva as the control number to access the
online platform. If a Non-Registered Holder would like to appoint
another person to act as his/her authorized proxy, such proxy must
be submitted to Teva along with the proof of ownership.
Additional information for holders of ordinary shares and
ADSs on how to participate
- Access the meeting platform at www.meetingcenter.io/218625112
and enter the meeting password TEVA2020 and your 15-digit control
number (for holders of ADSs) or Israeli identification number or
company registration number (for holders of ordinary shares)
beginning on Tuesday, June 9, 2020 at 4:15 p.m., Israel time.
- To submit a question before or during the meeting, visit
www.meetingcenter.io/218625112 with your control number and click
on the messages icon to submit your question.
- If you encounter any technical difficulties with the meeting
platform on the date of the virtual 2020 Annual Meeting, technical
support will be available during this time and will remain
available until the virtual 2020 Annual Meeting has ended.
- Whether or not you plan to attend Teva’s virtual 2020 Annual
Meeting, we urge you to vote and submit your proxy in advance by
one of the methods described in the proxy materials for the 2020
Annual Meeting.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at http://www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to our business and operations
in general, including uncertainty regarding the magnitude,
duration, and geographic reach of the COVID-19 pandemic and its
impact on our business, financial condition, operations, cash
flows, and liquidity and on the economy in general; and other
factors discussed in this press release, in our Quarterly Report on
Form 10-Q for the first quarter of 2020 and in our Annual Report on
Form 10-K for the year ended December 31, 2019, including in the
sections captioned “Risk Factors” and “Forward Looking Statements.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200526005291/en/
IR Contacts United States Kevin C. Mannix (215) 591-8912
Ran Meir 972 (3) 926-7516
PR Contacts United States Kelley Dougherty (973) 832-2810
Israel Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024